NCT03951428 is a clinical trial of Menstrual Blood Screening Test in Cancer, sponsored by LifeStory Health Inc..

Who is sponsoring NCT03951428?

NCT03951428 is sponsored by LifeStory Health Inc..

What drugs are being tested in NCT03951428?

Interventions in NCT03951428: Menstrual Blood Screening Test.

Is NCT03951428 still recruiting?

NCT03951428 is currently status unknown. Last updated 15 May 2019.

Last reviewed 2019-05-15 · How we verify

NCT03951428

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Screening of Cancer Through Novel Female Specific Biomarkers

Status unknown Last updated 15 May 2019

What this trial tests

trial testing Menstrual Blood Screening Test in Cancer in 60 participants. Status unknown.

Timeline

15 May 2019

Primary endpoint
1 November 2019

31 December 2019

Quick facts

Lead sponsor	LifeStory Health Inc.
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	15 May 2019
Primary completion	1 November 2019
Estimated completion	31 December 2019
Sites	1 location across United States

Drugs / interventions tested

Menstrual Blood Screening Test

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

LifeStory Health Inc.

Who can join

18 and older, female only, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Can reliable biomarkers be identified for detection of cancer at early stages using menstrual blood (MB)? Preliminary mass spectrometry (MS) results suggest that MB provides biomarkers for identification of disease such as cancers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. · · 2023 · cited 72× · PMID 36980276 · DOI 10.3390/cells12060935
Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03951428 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LifeStory Health Inc.
Last refreshed: 15 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing